MetaCap

Corcept Therapeutics Incorporated (CORT)

NASDAQ: CORTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

63.62-1.36 (-2.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CORT stock chart

Technical analysis

Key statistics

All statistics
52-week range
28.66 – 126.38
Day range
62.81 – 65.13
Volume / Avg
1.09M / 1.26M
Beta
—

52-week range

$28.66$126.38

CORT stock today

On Nov 20, CORT ended the session at $63.62, shedding $1.36 (2.09%), versus the S&P 500's 3.70% decline. At this level, CORT sits in the middle of its 52-week range of $28.66 to $126.38: 49.7% below the high, set on Aug 25, 2026 and 122.0% above the low. CORT is up 82.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 17.7%.

Corcept Therapeutics trades at 47.8x its trailing twelve-month earnings per share of $1.33. Its forward P/E of 12.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Corcept Therapeutics

Company profile

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Joseph K. Belanoff M.D.
Headquarters
Redwood City, CA
Employees
730
IPO year
2004

Financial highlights

Full financials

In fiscal 2025, Corcept Therapeutics generated $761.4 million in revenue, up 12.8% from fiscal 2024, its 13th consecutive year of revenue growth. Net income was $99.7 million (-29.4% year over year), for a net margin of 13.1% versus a median of 25.2% in the prior 5 years. Gross margin was 98.3% (down from 98.4%) and operating margin 5.9%.

Corcept Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$761.41M$675.04M$482.38M$401.86M$365.98M
Growth+12.79%+39.94%+20.04%+9.80%+3.42%
Net income$99.65M$141.21M$106.14M$101.42M$112.51M
EPS (diluted)$0.82$1.23$0.94$0.87$0.89

Analyst forecast

Forecast

Consensus (5 analysts)

buy

Avg. price target

$142.60+124.14%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 1
  • Strong sell 0

Target range

Low $50.00High $173.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$1.01 vs $0.68
Surprise
+48.53%

CORT news

All CORT news

Corcept Therapeutics peers

Health Care sector
CORT peer companies
CompanyPrice% ChgMarket capCompare
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs CORT
AXSMAxsome Therapeutics Inc.129.36-4.66%$6.80Bvs CORT
AMRXAmneal Pharmaceuticals Inc. Class A21.12-1.26%$7.36Bvs CORT
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs CORT
ABVXAbivax SA ADR73.20-9.24%$6.41Bvs CORT
ALKSAlkermes plc44.94-2.69%$7.55Bvs CORT
MIRMMirum Pharmaceuticals Inc.96.13+0.65%$6.28Bvs CORT
RYTMRhythm Pharmaceuticals Inc.112.36-3.80%$7.79Bvs CORT

Indexes, lists and sector

Corcept Therapeutics stock FAQ

What is Corcept Therapeutics's stock price today?

CORT last traded at $63.62 as of Nov 20, 4:00 PM EST, down 2.09% on the day. Prices are delayed at least 15 minutes.

What is CORT's P/E ratio?

CORT trades at a trailing P/E ratio of 47.83 and a forward P/E of 12.77.

Who is Corcept Therapeutics's CEO?

Dr. Joseph K. Belanoff M.D. is the chief executive officer of Corcept Therapeutics Incorporated, which has about 730 employees.

What is the CORT 52-week high?

The 52-week high for CORT is $126.38 and the 52-week low is $28.66. The stock is currently 49.7% below its high.

Compare CORT